1. Home
  2. LIXT vs POAS Comparison

LIXT vs POAS Comparison

Compare LIXT & POAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

N/A

Current Price

$2.88

Market Cap

26.5M

Sector

Health Care

ML Signal

N/A

POAS

Phaos Technology Holdings (Cayman) Limited Class A Ordinary Shares

N/A

Current Price

$2.05

Market Cap

22.9M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
LIXT
POAS
Founded
2005
2017
Country
United States
Singapore
Employees
3
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
26.5M
22.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LIXT
POAS
Price
$2.88
$2.05
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
41.6K
165.6K
Earning Date
05-11-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.64
$0.53
52 Week High
$6.09
$7.40

Technical Indicators

Market Signals
Indicator
LIXT
POAS
Relative Strength Index (RSI) 48.07 54.17
Support Level $2.50 $1.40
Resistance Level $3.30 $2.27
Average True Range (ATR) 0.24 0.18
MACD 0.03 0.13
Stochastic Oscillator 51.56 85.71

Price Performance

Historical Comparison
LIXT
POAS

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

About POAS Phaos Technology Holdings (Cayman) Limited Class A Ordinary Shares

Phaos Technology Holdings Cayman Ltd is an investment holding company incorporated in the Cayman Islands. Through its subsidiaries, the Company engages in the research, development, manufacturing, and commercialization of advanced optical technologies and products. Leveraging its patented microsphere technology, Phaos enhances the magnification of traditional optical microscopes, enabling visualization beyond the 200nm optical limit at a commercially viable working distance. The Company offers advanced microscopy equipment and parts, along with AI-powered software solutions that complement its hardware to deliver fully integrated microscopy systems. Its technologies serve diverse sectors, including manufacturing, biomedical, and research.

Share on Social Networks: